Ankasa Generates First Tranche of Planned $17M Series A
June 25, 2015
Ankasa Regenerative Therapeutics has raised $8.5 million in the first tranche of its Series A financing; the company intends to close the round on $17 million. Ankasa is focused on the development of the stem cell growth factor WNT3A, which is found in humans and functions in the maintenance of bone growth and repair. Ankasa plans to initially develop a therapy involving WNT3A for spinal fusion surgery patients before exploring additional bone and tissue repair applications.